The Current Ratio as of November 2024 (TTM) for Design Therapeutics, Inc. (DSGN) is 41.42

According to Design Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 41.42. This represents a change of 24.22% compared to the average of 33.34 of the last 4 quarters.

Design Therapeutics, Inc. (DSGN) Historical Current Ratio (quarterly & annually)

How has DSGN Current Ratio performed in the past?

The mean historical Current Ratio of Design Therapeutics, Inc. over the last ten years is 29.84. The current 41.42 Current Ratio has changed 13.78% with respect to the historical average. Over the past ten years (40 quarters), DSGN's Current Ratio was at its highest in in the June 2021 quarter at 118.91. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Design Therapeutics, Inc. (DSGN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Design Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Design Therapeutics, Inc. (DSGN) Average Current Ratio

How has DSGN Current Ratio performed in the past?

The current Current Ratio of Design Therapeutics, Inc. (DSGN) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Design Therapeutics, Inc. (DSGN) Current Ratio vs. Peers

How is DSGN’s Current Ratio compared to its peers?

Design Therapeutics, Inc.’s Current Ratio is greater than Monte Rosa Therapeutics, Inc. (6.56), greater than Werewolf Therapeutics, Inc. (12.13), greater than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), greater than Achilles Therapeutics plc (8.24), greater than Neoleukin Therapeutics, Inc. (15.33), greater than Magenta Therapeutics, Inc. (14.64), greater than Graphite Bio, Inc. (11.47), greater than ALX Oncology Holdings Inc. (4.39), greater than Aadi Bioscience, Inc. (4.20), greater than ADC Therapeutics SA (6.17), less than AlloVir, Inc. (55.08), greater than Gracell Biotechnologies Inc. (7.73), greater than Theseus Pharmaceuticals, Inc. (29.93), greater than Erasca, Inc. (16.79), greater than Cullinan Oncology, Inc. (28.87), greater than Immunocore Holdings plc (5.17), greater than C4 Therapeutics, Inc. (6.31),

Build a custom stock screener for Design Therapeutics, Inc. (DSGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Design Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Design Therapeutics, Inc. (DSGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Design Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.